复星医药子公司新药FCN-159片已被纳入突破性治疗药物程序

财中社
May 12, 2025

5月12日,复星医药(600196/02196)发布公告,控股子公司上海复星医药产业发展有限公司的FCN-159片已被纳入突破性治疗药物程序,用于治疗儿童朗格汉斯组织细胞增生症。该新药为集团自主研发的创新型小分子化学药物,为MEK1/2选择性抑制剂,拟主要用于治疗晚期实体瘤、1型神经纤维瘤病、树突状细胞和组织细胞肿瘤、低级别脑胶质瘤等。截至2025年4月,集团针对该新药的累计研发投入约为5.98...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10